Desethyl KB-3022 is the primary active metabolite of the novel antiplatelet drug KBT-3022; it prolongs the time required to achieve thrombotic occlusion in the femoral artery and inhibits collagen-induced platelet aggregation in whole blood ex vivo in a dose-dependent manner; it also inhibits thrombin-induced aggregation of washed platelets in a concentration-dependent manner (1–40 μM).